Table 2.
Variable | Graft survival rate (SEM), % |
p value | |||
---|---|---|---|---|---|
1-year | 3-year | 5-year | 10-year | ||
Recipient age group (yrs) | 0.19 | ||||
3–6 | 80 (7) | 80 (7) | 80 (7) | 40 (10) | |
7–10 | 88 (2) | 83 (3) | 83 (3) | 69 (6) | |
11–14 | 96 (1) | 81 (4) | 76 (5) | 76 (5) | |
15–18 | 86 (4) | 81 (4) | 81 (4) | 59 (8) | |
Recipient sex | 0.34 | ||||
Male | 85 (3) | 77 (3) | 77 (3) | 64 (6) | |
Female | 94 (2) | 87 (3) | 85 (3) | 62 (6) | |
Dialysis status before the transplantation | 0.006 | ||||
Pre-emptive transplantation | 91 (3) | 86 (4) | 86 (4) | 86 (4) | |
Hemodialysis | 90 (2) | 83 (3) | 83 (3) | 60 (6) | |
Peritoneal dialysis | 84 (8) | 67 (11) | 67 (11) | 33 (14) | |
Dialysis duration before the transplantation (yrs) | 0.003 | ||||
<1 | 87 (5) | 58 (7) | 58 (7) | 29 (12) | |
1–3 | 91 (3) | 86 (4) | 86 (4) | 75 (6) | |
>3 | 88 (6) | 88 (6) | 88 (6) | 53 (11) | |
Immunosuppressive regimen | 0.001 | ||||
Steroid + CSA + AZA | 78 (5) | 55 (6) | 49 (6) | 34 (7) | |
Steroid + CSA + MMF | 94 (2) | 89 (3) | 89 (3) | 76 (7) | |
Steroid + MMF + TAC | 80 (6) | 80 (6) | 80 (6) | NA* | |
Steroid + MMF + SRL | 92 (3) | 92 (3) | 80 (5) | NA | |
Presence of acute rejection | 0.002 | ||||
Yes | 79 (4) | 69 (4) | 69 (4) | 52 (7) | |
No | 93 (1) | 87 (2) | 85 (2) | 66 (4) | |
Donor type | 0.002 | ||||
Living related | 100 (0) | 100 (0) | 100 (0) | 100 (0) | |
Living unrelated | 88 (2) | 80 (2) | 79 (2) | 60 (4) | |
Deceased brain-dead | 85 (8) | 85 (8) | 85 (8) | 42 (17) | |
Donor age group (yrs) | 0.054 | ||||
<20 | 72 (13) | 72 (13) | 72 (13) | 72 (13) | |
20–40 | 87 (2) | 86 (2) | 86 (2) | 60 (7) | |
>40 | 93 (3) | 89 (4) | 89 (4) | 89 (4) | |
Donor sex | 0.078 | ||||
Male | 89 (2) | 86 (2) | 86 (3) | 73 (5) | |
Female | 85 (4) | 85 (4) | 85 (4) | 56 (10) |
AZA: azathioprine, CSA: cyclosporine, MMF: mycophenolate mofetil, NA: not applicable, SEM: standard error of the mean, SRL: sirolimus, TAC: tacrolimus